Patents for A61P 19 - Drugs for skeletal disorders (81,981)
04/2002
04/24/2002CN1346266A Analgesic regimen
04/24/2002CN1083276C Chinese-medicinal capsule for treating osteonecrosis
04/23/2002US6376665 Antiarthritic agents, antiinflammatory agents
04/23/2002US6376654 Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
04/23/2002US6376653 Tie2 antagonist antibodies
04/23/2002US6376519 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
04/23/2002US6376502 Osteoporosis compounds
04/23/2002US6376493 Selective inhibition of phosphodiesterase iv and tumor necrosis factor; useful in treating osteoporosis, tumors, autoimmune diseases, rheumatic diseases, and asthma
04/23/2002US6376489 Cyclic AMP-specific phosphodiesterase inhibitors
04/23/2002US6376476 Isoprenoid pathway inhibitors for stimulating bone growth
04/23/2002CA2300386C Method for treating dystonia with botulinum toxin types c,d and e
04/18/2002WO2002031514A2 A method of determining the initial dose of vitamin d compounds
04/18/2002WO2002031511A2 Modulation of ligand binding/enzymatic activity of alpha beta proteins
04/18/2002WO2002031115A2 Nucleic acid molecules and polypeptides for immune modulation
04/18/2002WO2002030982A2 Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
04/18/2002WO2002030938A1 Benzhydryl derivatives
04/18/2002WO2002030924A1 Quinazoline derivatives with anti-tumour activity
04/18/2002WO2002030911A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis
04/18/2002WO2002030910A1 (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
04/18/2002WO2002030908A1 Inhibitors of protein kinases
04/18/2002WO2002030904A1 Pyridinone derivatives for treatment of atherosclerosis
04/18/2002WO2002030895A1 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS
04/18/2002WO2002030888A2 Tricyclic compounds and uses thereof
04/18/2002WO2002030876A2 Cyclic carboxylic acids as integrin antagonists
04/18/2002WO2002030874A2 Aliphatic, cyclic amino carboxylic acids as integrin antagonists
04/18/2002WO2002030873A1 Mmp inhibitor
04/18/2002WO2002030473A1 Targeted therapeutic agents
04/18/2002WO2002030453A1 Methods of inhibiting angiogenesis using nadph oxidase inhibitors
04/18/2002WO2002030423A1 NF-λB INHIBITORS
04/18/2002WO2002030407A1 ESTROGEN RECEPTOR-β LIGANDS
04/18/2002WO2002030353A2 NF-λB INHIBITORS
04/18/2002WO2002017914A3 Fused pyrrolocarbazoles against inflammation
04/18/2002WO2002012210A9 Biphenyl derivatives and their use as ppar-gamma receptor activators
04/18/2002WO2002008272A3 High affinity soluble interleukin-18 receptor
04/18/2002WO2002008217A3 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
04/18/2002WO2002006478A3 Extracellular matrix protein
04/18/2002WO2002002541A3 Inhibitors of copper-containing amine oxidases
04/18/2002WO2001082952A3 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
04/18/2002WO2001072777A3 Human transcription factors
04/18/2002WO2001068570A3 Il-8 receptor antagonists
04/18/2002WO2001068569A3 Il-8 receptor antagonists
04/18/2002WO2001068075A3 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
04/18/2002WO2001068070A3 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
04/18/2002WO2001058916A3 Antibodies to ccr5
04/18/2002WO2001058893A3 Indol-3-yl derivatives and their use as integrin inhibitors
04/18/2002WO2001026644A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto
04/18/2002WO2000068385A9 Novel nucleic acids and proteins with growth hormone activity
04/18/2002WO2000066106A9 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
04/18/2002US20020045645 Lactone integrin antagonists
04/18/2002US20020045642 Antiinflammatory, -arthritic and -emetic agents; central nervous system disorders; Parkinson's disease; antidepressants; psychological disorders; anxiolytic agents; antagonists of substance P receptors
04/18/2002US20020045625 Oxazolidinone chemotherapeutic agents
04/18/2002US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders.
04/18/2002US20020045613 1-aroyl-piperidinyl benzamidines
04/18/2002US20020045597 N-acylated-2-glucosamine derivatives for treating osteoarthritis/inflammatory arthritis, and enhancing cartilage formulation, chondrocyte cell proliferation and glycosaminoglycan production
04/18/2002US20020045203 Method for detecting active ingredients of medical value
04/18/2002US20020044963 Cyclic AMP-specific phosphodiesterase inhibitors
04/18/2002DE10047319A1 Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können Use of R-arylpropionic acids for producing medicaments for treating diseases that can be therapeutically affected by the inhibition of activation of the nuclear transcription factor AP-1
04/18/2002CA2459746A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis
04/18/2002CA2427499A1 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents
04/18/2002CA2425581A1 Modulation of ligand binding/enzymatic activity of alpha beta proteins
04/18/2002CA2425508A1 Targeted therapeutic agents
04/18/2002CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation
04/18/2002CA2424292A1 Tricyclic compounds and uses thereof
04/18/2002CA2423316A1 A method of determining the initial dose of vitamin d compounds
04/18/2002CA2394084A1 Inhibitors of protein kinases
04/17/2002EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis
04/17/2002EP1197496A1 Novel peptides
04/17/2002EP1197488A1 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
04/17/2002EP1197213A2 Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
04/17/2002EP1196577A2 Cell cycle and proliferation proteins
04/17/2002EP1196574A2 Human proteins involved in detoxification
04/17/2002EP1196569A2 Electron transfer proteins
04/17/2002EP1196568A1 Human lim domain proteins
04/17/2002EP1196567A2 Human immune response molecules
04/17/2002EP1196560A1 Neurotrophic factor receptor gfr-alpha-4
04/17/2002EP1196450A1 Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis
04/17/2002EP1196441A1 Keratinocyte growth factor-2
04/17/2002EP1196440A2 Therapeutic peptides derived from subsequences of bpi
04/17/2002EP1196433A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6
04/17/2002EP1196416A1 Substituted purine derivatives as inhibitors of cell adhesion
04/17/2002EP1196414A1 Prodrugs of carbamate inhibitors of impdh
04/17/2002EP1196407A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors
04/17/2002EP1196404A1 Piperazine derivatives as modulators of chemokine receptor activity
04/17/2002EP1196395A1 Cyclized amino acid derivatives
04/17/2002EP1196390A2 Pyrazole compositions useful as inhibitors of erk
04/17/2002EP1196389A1 N-heterocyclic derivatives with neuronal activity
04/17/2002EP1196387A1 Azo amino acid derivatives for the treatment of neurological diseases
04/17/2002EP1196385A1 Beta-amino acid derivatives for the treatment of neurological diseases
04/17/2002EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
04/17/2002EP1196180A1 Treatment of angiogenesis dependent conditions with dextrin sulphate
04/17/2002EP1196175A1 Pharmaceutical tablets
04/17/2002EP1196169A1 Compounds having cytokine inhibitory activity
04/17/2002EP1196162A1 Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same
04/17/2002EP0937038B1 Vitamin d analogues
04/17/2002EP0906127B1 Novel devices for transdermal administering of trimegestone
04/17/2002EP0901378B1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
04/17/2002CN1345332A C-terminal modified (N-substituted)-2 indolylcarbonyldiptides as inhibitors of ICE/CED-3 family of cysteine proteases
04/17/2002CN1345331A Method and composition for angiogenesis inhibition
04/17/2002CN1345329A Tumor mecrosis factor receptors 6 alpha and beta
04/17/2002CN1345314A Amine derivatives as protease inhibitors